IP Library Granted Patent US 11,834,703
Granted Patent B2
US 11,834,703 · App. 17/473,524 · Granted Dec 5, 2023

Hybridization compositions and methods

Inventors: Charles M. Hansen (Horsholm, DK); Steen Hauge Matthiesen (Hillerød, DK); Kenneth H. Petersen (Smørum, DK); Tim Svenstrup Poulsen (Horsholm, DK)
Assignee: Agilent Technologies, Inc.
C12Q1/6832C12Q1/6841Y10T436/143333
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,834,703
App. No.
17/473,524
Granted
Dec 5, 2023
Kind
B2
Abstract

The invention provides methods and compositions for hybridizing at least one molecule to a target. The invention may, for example, eliminate the use of, or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least one nucleic acid sequence and at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences.

Claims (25)

1. A hybridization composition comprising a mixture of at least one nucleic acid sequence, at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences, an accelerating agent, and at least one additional component selected from the group consisting of: buffering agents, salts, chelating agents, detergents, and blocking agents,

wherein less than 10% of the hybridization composition is formamide,

wherein the polar aprotic solvent is not dimethyl sulfoxide (DMSO) and has lactone, sulfone, sulfite, and/or carbonate functional groups,

wherein the at least one nucleic acid sequence is a FISH or CISH probe;

wherein the at least one polar aprotic solvent comprises a polar aprotic solvent selected from the group consisting of:

and

wherein the accelerating agent is a polymer.

2. The hybridization composition according to claim 1 , wherein the accelerating agent is present at a concentration from 1%-80%.

3. The hybridization composition according to claim 1 , wherein the accelerating agent is selected from the group consisting of PVP, heparin, dextran sulfate, and combinations thereof.

4. The hybridization composition according to claim 1 , wherein the accelerating agent is dextran sulfate.

5. The hybridization composition according to claim 4 , wherein the composition comprising up to 10% dextran sulfate.

6. The hybridization composition according to claim 4 , wherein the composition comprises up to 20% dextran sulfate.

7. The hybridization composition according to claim 1 , wherein the concentration of polar aprotic solvent is 5% to 10% (v/v).

8. The hybridization composition according to claim 1 , wherein the concentration of polar aprotic solvent is 10% to 20% (v/v).

9. The hybridization composition according to claim 1 , wherein the concentration of polar aprotic solvent is 20% to 30% (v/v).

10. The hybridization composition according to claim 1 , with the proviso that the composition does not contain formamide.

11. The hybridization composition according to claim 1 , wherein the composition contains less than 2% formamide.

12. The hybridization composition according to claim 1 wherein the composition contains less than 1% formamide.

13. The hybridization composition according to claim 1 , wherein the polar aprotic solvent is selected from the group consisting of: 2,3-butylene carbonate, γ-butyrolactone, caprolactone (epsilon), chloro maleic anhydride, chloroethylene carbonate, chloronitromethane, citraconic anhydride, crotonlactone, 5-cyano-2-thiouracil, dimethyl sulfate, dimethyl sulfone, diphenyl sulfone, ethanesulfonylchloride, ethylene carbonate, ethylene glycol sulfate, glycol sulfite, methyl alpha bromo tetronate, methyl phenyl sulfone, methyl sulfolane, methyl-4-toluenesulfonate, N-phenyl sydnone, phthalic anhydride, 1,3-propane sultone, β-propiolactone, propylene carbonate, saccharin, sulfanilamide, sulfolane, trimethylene sulfide-dioxide, and trimethylene sulfite.

14. The hybridization composition according to claim 1 , wherein the hybridization composition comprises at least one buffering agent and at least one salt.

15. The hybridization composition according to claim 14 , wherein the salt is NaCl and/or the buffering agent is phosphate buffer.

16. The hybridization composition according to claim 15 , wherein the accelerating agent is dextran sulfate present at a concentration of 10% to 40%, and wherein the NaCl is present at a concentration of 0 mM to 1200 mM, and/or the phosphate buffer is present at a concentration of 0 mM to 50 mM.

17. The hybridization composition according to claim 15 , wherein the dextran sulfate is present at a concentration of 10% to 30%, the NaCl is present at a concentration of 300 mM to 600 mM, and/or the phosphate buffer is present at a concentration of 5 mM to 20 mM.

18. The hybridization composition according to claim 1 , wherein the at least one nucleic acid sequence is a FISH DNA probe.

19. The hybridization composition according to claim 1 , wherein the at least one nucleic acid sequence comprises a detectable label.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2022
From: MATTHIESEN, STEEN HAUGE; PETERSEN, KENNETH H.; POULSEN, TIM SVENSTRUP; HANSEN, CHARLES M.
To: DAKO DENMARK A/S
Reel/Frame 058882/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2022
From: DAKO DENMARK APS
To: AGILENT TECHNOLOGIES, INC.
Reel/Frame 058882/0382 →
CHANGE OF NAME Recorded Feb 3, 2022
From: DAKO DENMARK A/S
To: DAKO DENMARK APS
Reel/Frame 058950/0631 →
Priority Claims (2)
DK PA200800727 · May 27, 2008 · national
DK PA200900278 · Feb 27, 2009 · national
Continuity (4)
Continuation 12994492
Provisional Application 61155683 · Feb 26, 2009
Provisional Application 61056089 · May 27, 2008
Related Publication 20220064716A1 · Mar 3, 2022
Cited By (1)
US 12,534,755